{"id":63302,"date":"2026-04-16T17:25:57","date_gmt":"2026-04-16T09:25:57","guid":{"rendered":"https:\/\/flcube.com\/?p=63302"},"modified":"2026-04-16T17:25:58","modified_gmt":"2026-04-16T09:25:58","slug":"daiichi-sankyo-to-divest-healthcare-subsidiary-to-suntory-in-1-6-billion-strategic-realignment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63302","title":{"rendered":"Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment"},"content":{"rendered":"\n<p><strong>Daiichi Sankyo Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4568:TYO\">TYO: 4568<\/a>) has announced an agreement to transfer all shares of its subsidiary, <strong>Daiichi Sankyo Healthcare Co., Ltd. (DSHC)<\/strong>, to <strong>Suntory Holdings Limited<\/strong> for a total consideration of <strong>JPY 246.5 billion (USD 1.6 billion)<\/strong>. The transaction will be executed in stages, with Daiichi Sankyo transferring <strong>30% of DSHC&#8217;s outstanding shares<\/strong> to Suntory in <strong>June 2026<\/strong>, and completing the full divestiture by <strong>June 2029<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Seller<\/strong><\/td><td>Daiichi Sankyo Co., Ltd. (TYO: 4568)<\/td><\/tr><tr><td><strong>Buyer<\/strong><\/td><td>Suntory Holdings Limited (private)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Daiichi Sankyo Healthcare Co., Ltd. (DSHC)<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td>JPY 246.5 billion (USD 1.6 billion)<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>Staged share transfer (30% in June 2026, 100% by June 2029)<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Portfolio optimization and strategic focus realignment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-business-profile-daiichi-sankyo-healthcare\">Business Profile \u2013 Daiichi Sankyo Healthcare<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Segments:<\/strong> Over-the-counter (OTC) pharmaceuticals and consumer healthcare products<\/li>\n\n\n\n<li><strong>Extended Portfolio:<\/strong> Functional skincare, oral care, and food products<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> Established Japanese healthcare brand with nationwide distribution<\/li>\n\n\n\n<li><strong>Revenue Contribution:<\/strong> Represented approximately 8% of Daiichi Sankyo&#8217;s consolidated revenue in FY2025<\/li>\n\n\n\n<li><strong>Employee Base:<\/strong> Approximately 1,200 employees across manufacturing, sales, and R&amp;D functions<\/li>\n<\/ul>\n\n\n\n<p>DSHC has built a strong reputation in Japan&#8217;s competitive OTC market, with leading positions in digestive health, pain relief, and cold\/flu remedies, while expanding into adjacent wellness categories including functional foods and premium skincare.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-daiichi-sankyo\">For Daiichi Sankyo<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Focus:<\/strong> Reallocates management resources to prioritize <strong>innovative pharmaceutical businesses<\/strong>, particularly in <strong>oncology<\/strong><\/li>\n\n\n\n<li><strong>Capital Allocation:<\/strong> Generates significant cash proceeds to fund R&amp;D investments in high-value therapeutic areas<\/li>\n\n\n\n<li><strong>Operational Streamlining:<\/strong> Reduces complexity by separating consumer healthcare from core prescription pharmaceutical operations<\/li>\n\n\n\n<li><strong>Growth Strategy:<\/strong> Aligns with company&#8217;s &#8220;2030 Vision&#8221; to become a global leader in oncology therapeutics<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-suntory-holdings\">For Suntory Holdings<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Category Expansion:<\/strong> Leverages existing <strong>food and health business foundation<\/strong> to accelerate DSHC&#8217;s growth trajectory<\/li>\n\n\n\n<li><strong>Synergy Potential:<\/strong> Integrates DSHC&#8217;s healthcare expertise with Suntory&#8217;s established distribution network and consumer insights<\/li>\n\n\n\n<li><strong>Wellness Ecosystem:<\/strong> Strengthens position in Japan&#8217;s growing preventive health and wellness market<\/li>\n\n\n\n<li><strong>Brand Portfolio:<\/strong> Adds established pharmaceutical-grade brands to complement existing beverage and food offerings<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-market-context\">Financial Impact &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Japan OTC Market:<\/strong> Valued at JPY 2.1 trillion (USD 13.6 billion) in 2025, growing at 3.2% CAGR driven by aging population and self-medication trends<\/li>\n\n\n\n<li><strong>Consumer Healthcare Trends:<\/strong> Increasing demand for science-backed wellness products bridging pharmaceutical efficacy and consumer convenience<\/li>\n\n\n\n<li><strong>Daiichi Sankyo Oncology Pipeline:<\/strong> Currently includes 12 late-stage assets, with 4 expected to achieve regulatory approval by 2028<\/li>\n\n\n\n<li><strong>Transaction Multiples:<\/strong> Implied EV\/Sales multiple of 2.8x based on DSHC&#8217;s FY2025 revenue, consistent with recent Japanese healthcare M&amp;A transactions<\/li>\n<\/ul>\n\n\n\n<p>&#8220;This strategic divestiture enables us to sharpen our focus on becoming a global oncology leader while ensuring DSHC&#8217;s continued success under Suntory&#8217;s stewardship,&#8221; said Sunao Manabe, Representative Director, President and CEO of Daiichi Sankyo. &#8220;Suntory&#8217;s deep expertise in consumer health and wellness makes them the ideal partner to unlock DSHC&#8217;s full potential.&#8221;<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding transaction completion, strategic realignment, and business prospects. Actual results may differ due to risks including regulatory approvals, integration challenges, market conditions, and competitive dynamics in Japan&#8217;s healthcare sector.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Daiichi Sankyo Co., Ltd. (TYO: 4568) has announced an agreement to transfer all shares of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[194,78,978],"class_list":["post-63302","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-daiichi-sankyo","tag-otc-retail","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Daiichi Sankyo Co., Ltd. (TYO: 4568) has announced an agreement to transfer all shares of its subsidiary, Daiichi Sankyo Healthcare Co., Ltd. (DSHC), to Suntory Holdings Limited for a total consideration of JPY 246.5 billion (USD 1.6 billion). The transaction will be executed in stages, with Daiichi Sankyo transferring 30% of DSHC&#039;s outstanding shares to Suntory in June 2026, and completing the full divestiture by June 2029.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63302\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment\" \/>\n<meta property=\"og:description\" content=\"Daiichi Sankyo Co., Ltd. (TYO: 4568) has announced an agreement to transfer all shares of its subsidiary, Daiichi Sankyo Healthcare Co., Ltd. (DSHC), to Suntory Holdings Limited for a total consideration of JPY 246.5 billion (USD 1.6 billion). The transaction will be executed in stages, with Daiichi Sankyo transferring 30% of DSHC&#039;s outstanding shares to Suntory in June 2026, and completing the full divestiture by June 2029.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63302\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T09:25:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-16T09:25:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63302#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63302\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment\",\"datePublished\":\"2026-04-16T09:25:57+00:00\",\"dateModified\":\"2026-04-16T09:25:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63302\"},\"wordCount\":507,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Daiichi Sankyo\",\"OTC \\\/ retail\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63302#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63302\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63302\",\"name\":\"Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-16T09:25:57+00:00\",\"dateModified\":\"2026-04-16T09:25:58+00:00\",\"description\":\"Daiichi Sankyo Co., Ltd. (TYO: 4568) has announced an agreement to transfer all shares of its subsidiary, Daiichi Sankyo Healthcare Co., Ltd. (DSHC), to Suntory Holdings Limited for a total consideration of JPY 246.5 billion (USD 1.6 billion). The transaction will be executed in stages, with Daiichi Sankyo transferring 30% of DSHC's outstanding shares to Suntory in June 2026, and completing the full divestiture by June 2029.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63302#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63302\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63302#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment - Insight, China&#039;s Pharmaceutical Industry","description":"Daiichi Sankyo Co., Ltd. (TYO: 4568) has announced an agreement to transfer all shares of its subsidiary, Daiichi Sankyo Healthcare Co., Ltd. (DSHC), to Suntory Holdings Limited for a total consideration of JPY 246.5 billion (USD 1.6 billion). The transaction will be executed in stages, with Daiichi Sankyo transferring 30% of DSHC's outstanding shares to Suntory in June 2026, and completing the full divestiture by June 2029.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63302","og_locale":"en_US","og_type":"article","og_title":"Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment","og_description":"Daiichi Sankyo Co., Ltd. (TYO: 4568) has announced an agreement to transfer all shares of its subsidiary, Daiichi Sankyo Healthcare Co., Ltd. (DSHC), to Suntory Holdings Limited for a total consideration of JPY 246.5 billion (USD 1.6 billion). The transaction will be executed in stages, with Daiichi Sankyo transferring 30% of DSHC's outstanding shares to Suntory in June 2026, and completing the full divestiture by June 2029.","og_url":"https:\/\/flcube.com\/?p=63302","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-16T09:25:57+00:00","article_modified_time":"2026-04-16T09:25:58+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63302#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63302"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment","datePublished":"2026-04-16T09:25:57+00:00","dateModified":"2026-04-16T09:25:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63302"},"wordCount":507,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Daiichi Sankyo","OTC \/ retail","TYO: 4568"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63302#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63302","url":"https:\/\/flcube.com\/?p=63302","name":"Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-16T09:25:57+00:00","dateModified":"2026-04-16T09:25:58+00:00","description":"Daiichi Sankyo Co., Ltd. (TYO: 4568) has announced an agreement to transfer all shares of its subsidiary, Daiichi Sankyo Healthcare Co., Ltd. (DSHC), to Suntory Holdings Limited for a total consideration of JPY 246.5 billion (USD 1.6 billion). The transaction will be executed in stages, with Daiichi Sankyo transferring 30% of DSHC's outstanding shares to Suntory in June 2026, and completing the full divestiture by June 2029.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63302#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63302"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63302#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo to Divest Healthcare Subsidiary to Suntory in $1.6 Billion Strategic Realignment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63302"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63302\/revisions"}],"predecessor-version":[{"id":63303,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63302\/revisions\/63303"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63302"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}